Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry-Reference-Cited by-同舟云学术

Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry

Published:2021-11-25 Issue:1 Volume:17 Page:35-41
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Alawawdeh Anas,Piantadosi Cynthia,Townsend Amanda Rose,Karapetis Christos Stelios,Padbury Rob,Roy Amitesh Chandra,Moore James,Maddern Guy,Roder David,Smith Annabelle,Price Timothy Jay^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-021-00856-9.pdf

Reference33 articles.

1. Ni D, Li X, He X, Zhang H, Zhang J, Lu S. Drugging K-RasG12C through covalent inhibitors: mission possible? Pharmacol Ther. 2019;202:1–7.

2. Christensen JG, Olson P, Briere T, Wiel C, Bergo MO. Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor. J Intern Med. 2020;288(2):183–91.

3. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–9.

4. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17–33.

5. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–51.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial;Nature Medicine;2024-01

2. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review;The Oncologist;2023-07-11

3. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics;Critical Reviews in Oncology/Hematology;2023-06